Your browser doesn't support javascript.
loading
Adjunctive continuous theta burst stimulation for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled studies.
Cai, Dong-Bin; Qin, Xiu-De; Qin, Zhen-Juan; Lan, Xian-Jun; Wang, Jian-Jun; Ng, Chee H; Zheng, Wei; Xiang, Yu-Tao.
Afiliação
  • Cai DB; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
  • Qin XD; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
  • Qin ZJ; The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, China.
  • Lan XJ; The Brain Hospital of Guangxi Zhuang Autonomous Region, LiuZhou, China.
  • Wang JJ; Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, China.
  • Ng CH; Department of Psychiatry, The Melbourne Clinic and St Vincent's Hospital, University of Melbourne, Richmond, Victoria, Australia. Electronic address: cng@unimelb.edu.au.
  • Zheng W; The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China. Electronic address: zhengwei0702@163.com.
  • Xiang YT; Unit of Psychiatry, Department of Public Health and Medicinal Administration, & Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Macao SAR, China; Centre for Cognitive and Brain Sciences, University of Macau, Macao SAR, China.. Electronic address: xyutly@gmai
J Affect Disord ; 346: 266-272, 2024 02 01.
Article em En | MEDLINE | ID: mdl-37924984
ABSTRACT

OBJECTIVES:

As a novel type of theta burst stimulation (TBS), continuous TBS (cTBS) has been shown to have mixed therapeutic effects for major depressive disorder (MDD) or bipolar depression (BD). Thus, we performed a meta-analysis of randomized controlled trials (RCTs) of cTBS for treating major depressive episodes in patients with MDD or BD.

METHODS:

A systematic search of four major bibliographic databases (PubMed, EMBASE, Cochrane Library, and PsycINFO) was conducted from inception dates to February 3, 2023 to identify eligible studies. The data were analyzed using a random-effects model.

RESULTS:

Three RCTs (n = 78, active cTBS = 37 and sham cTBS = 41) were included the meta-analysis. No significant differences were found in terms of change in Hamilton Depression Rating Scale (HAMD) scores (3 RCTs, n = 78, SMD = -0.09, 95 % CI -0.53 to 0.36; I2 = 0 %; P = 0.71) and study-defined response (2 RCTs, n = 58, 26.7 % versus 21.4 %, RR = 1.20, 95 % CI 0.48 to 2.96; I2 = 0 %; P = 0.70) between active and sham cTBS groups. Similarly, no group differences were found in the rates of adverse events and discontinuation due to any reason (P > 0.05).

LIMITATIONS:

Meta-analysis had small sample sizes and low number of included studies.

CONCLUSIONS:

Although cTBS appeared to be a safe and well-tolerated option for treating major depressive episodes in MDD or BD patients, no advantage in treatment effects was found in this meta-analysis. Future large-scale studies are warranted to assess the efficacy of cTBS for MDD or BD patients with a major depressive episode.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transtorno Bipolar / Transtorno Depressivo Maior Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: J Affect Disord Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Transtorno Bipolar / Transtorno Depressivo Maior Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Revista: J Affect Disord Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China